Edesa Biotech Reports Fiscal 3rd Quarter 2021 Financial Results
Edesa Biotech (NASDAQ:EDSA) reported its financial results for Q3 and the nine months ending June 30, 2021. The company achieved key milestones in clinical programs EB05 and EB01, with recommendations to advance both to final enrollment stages. R&D expenditures increased to $4.46 million, reflecting enhanced clinical study activities. Edesa recorded no revenues for the quarter, leading to a net loss of $4.76 million ($0.36 per share). For the nine-month period, total operating expenses rose to $18.20 million amid no revenues, resulting in a net loss of $9.66 million ($0.83 per share).
- Key milestones achieved in clinical programs EB05 and EB01.
- Independent boards recommended advancing both programs to final enrollment stages.
- Increased grant income, totaling approximately $8.54 million for the nine months.
- No revenues reported for the three or nine months ended June 30, 2021.
- Net loss increased to $4.76 million for Q3, up from $1.77 million year-over-year.
- Total operating expenses rose significantly, reaching $18.20 million over nine months.
TORONTO, ON / ACCESSWIRE / August 13, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and nine months ended June 30, 2021 and provided an update on its business.
During the quarter, the company achieved key interim milestones for both of its lead product candidates, EB05 and EB01. Independent monitoring boards assessed blinded interim treatment data and based on their positive findings recommended that the two development programs advance to the final stages of enrollment. Edesa expects the end of Phase 2 (interim) analysis of a Phase 2/3 study of EB05 as a single-dose treatment for hospitalized COVID-19 patients will be completed as early as the current quarter. The company plans to provide more detailed clinical updates as they become available. In parallel, the company has begun patient randomizations for the final part of a Phase 2b clinical study evaluating EB01 as a monotherapy for chronic Allergic Contact Dermatitis. Edesa recently added new investigational sites and expanded recruitment beyond the U.S. to Canada.
"We are pleased to have these two key programs advancing side by side toward data readouts and value inflection opportunities. EB05 and EB01 each represent novel anti-inflammatory technologies with the potential to provide transformational therapies for a broad range of inflammatory and autoimmune conditions," said Par Nijhawan, MD, Chief Executive Officer of Edesa Biotech. "We look forward to maintaining the momentum we achieved year to date, and announcing our end of Phase 2 results of our EB05 program as soon as available."
Edesa's Chief Financial Officer Kathi Niffenegger reported that expenditures for the fiscal third quarter were in line with management's expectations and driven primarily by incremental clinical study expenses related to patient enrollment, expanded operations and drug product-related costs. "Our R&D expenditures for the three-month and nine-month periods have largely tracked the accelerated progress of our clinical studies as well as preparations related to commercial-scale manufacturing of our product candidates," she said.
For the nine-month period ended June 30, 2021, Ms. Niffenegger reported that the company recorded reimbursements of approximately
Financial Results for the three months Ended June 30, 2021
There were no revenues for the three months ended June 30, 2021 compared to
Total operating expenses increased by
- Research and development expenses increased by
$3.32 million to$4.46 million for the three months ended June 30, 2021 compared to$1.14 million for the same period last year primarily due to increased external research expenses related to recruitment and enrollment in the company's ongoing clinical studies, increased investigational drug product expenses and an increase in noncash share-based compensation. Higher salary and related personnel expenses and patent fees also contributed to the increase. - General and administrative expenses increased by
$0.88 million to$1.61 million for the three months ended June 30, 2021 compared to$0.73 million for the same period last year primarily as a result of higher salary and related personnel expenses, noncash share-based compensation and increased headcount. Higher legal and other professional services also contributed to the increase.
Total other income increased by
For the three months ended June 30, 2021, Edesa reported a net loss of
Financial Results for the Nine Months Ended June 30, 2021
There were no revenues for the nine months ended June 30, 2021 compared to
Total operating expenses increased by
- Research and development expenses increased by
$11.65 million to$13.82 million for the nine months ended June 30, 2021 compared to$2.17 million for the same period last year primarily due to milestone payments related to advancement of the company's EB05 clinical program, increased external research expenses related to accelerated activity in the company's ongoing clinical studies, increased investigational drug product expenses and an increase in noncash share-based compensation. Higher salary and related personnel expenses and patent fees also contributed to the increase. - General and administrative expenses increased by
$1.85 million to$4.38 million for the nine months ended June 30, 2021 compared to$2.53 million for the same period last year primarily as a result of higher salary and related personnel expenses, noncash share-based compensation and increased headcount. Higher legal and other professional services also contributed to the increase.
Total other income increased by
For the nine months ended June 30, 2021, Edesa reported a net loss of
Event Calendar
Edesa management is scheduled to present at the H.C. Wainwright Global Investment Conference being held September 13-15, 2021 in New York City. Attendees interested in meeting with management can schedule one-on-one meetings through the conference or by contacting Edesa at investors@edesabiotech.com.
About Edesa Biotech, Inc.
Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. The company's two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy that the company is developing as a treatment for Acute Respiratory Distress Syndrome (ARDS). ARDS is a life-threatening form of respiratory failure, and the leading cause of death among COVID-19 patients. Edesa is also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. EB01 employs a novel, non-steroidal mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in ACD patients. The company is based in Markham, Ontario, Canada, with a U.S. subsidiary located in Southern California. Sign up for news alerts. Connect with Edesa on Twitter and LinkedIn.
Edesa Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions, including statements related to: upcoming milestones in the company's clinical studies, including the timing of enrollment milestones and data readouts for its COVID-19 and dermatitis studies; the company's belief that its product candidates may provide transformational therapies for a broad range of inflammatory and autoimmune conditions; and the company's intention to maintain the momentum it has achieved during 2021 and move another step closer to providing new, effective treatment options for patients. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises, such as COVID-19. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.
Contact
Gary Koppenjan
Edesa Biotech, Inc.
(805) 488-2800 ext. 150
investors@edesabiotech.com
| Condensed Interim Consolidated Statements of Operations (Unaudited) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| June 30, 2021 | June 30, 2020 | June 30, 2021 | June 30, 2020 | |||||||||||||
Total Revenues | $ | - | $ | 109,985 | $ | - | $ | 328,301 | ||||||||
Expenses: | ||||||||||||||||
Cost of sales | - | 1,472 | - | 15,287 | ||||||||||||
Research and development | 4,464,347 | 1,143,868 | 13,819,305 | 2,174,680 | ||||||||||||
General and administrative | 1,608,232 | 733,079 | 4,377,507 | 2,528,702 | ||||||||||||
| 6,072,579 | 1,878,4190 | 18,196,812 | 4,718,669 | |||||||||||||
Loss from Operations | (6,072,579 | ) | (1,768,434 | ) | (18,196,812 | ) | (4,390,368 | ) | ||||||||
Other Income (Loss): | ||||||||||||||||
Reimbursement grant income | 1,306,796 | - | 8,477,261 | - | ||||||||||||
Other income (loss) | 6,273 | 2,671 | 63,242 | 41,436 | ||||||||||||
Loss before income taxes | (4,759,510 | ) | (1,765,763 | ) | (9,656,309 | ) | (4,348,932 | ) | ||||||||
Income tax expense | - | - | 800 | 800 | ||||||||||||
Net Loss | (4,759,510 | ) | (1,765,763 | ) | (9,657,109 | ) | (4,349,732 | ) | ||||||||
Exchange differences on translation | 174,128 | 68,972 | 267,075 | 47,178 | ||||||||||||
Net Comprehensive Loss | $ | (4,585,382 | ) | $ | (1,696,791 | ) | $ | (9,390,034 | ) | $ | (4,302,554 | ) | ||||
Weighted average number of common shares | 13,251,999 | 8,859,520 | 11,680,294 | 8,364,866 | ||||||||||||
Loss per common share - basic and diluted | $ | (0.36 | ) | $ | (0.20 | ) | $ | (0.83 | ) | $ | (0.52 | ) | ||||
| Condensed Interim Consolidated Balance Sheets (Unaudited) | ||||||||
| June 30, 2021 | September 30, 2020 | |||||||
| Assets: | ||||||||
Cash and cash equivalents | $ | 8,052,574 | $ | 7,213,695 | ||||
Other current assets | 6,281,733 | 890,323 | ||||||
Non-current assets | 2,543,036 | 2,658,357 | ||||||
Total Assets | $ | 16,877,343 | $ | 10,762,375 | ||||
Liabilities, shareholders' equity and temporary equity: | ||||||||
Current liabilities | $ | 983,467 | $ | 1,529,857 | ||||
Noncurrent liabilities | 90,121 | 124,388 | ||||||
Temporary equity | - | 2,476,955 | ||||||
Shareholders' equity | 15,803,755 | 6,631,175 | ||||||
Total liabilities, shareholders' equity and temporary equity | $ | 16,877,343 | $ | 10,762,375 | ||||
| Condensed Interim Consolidated Statements of Cash Flows (Unaudited) | ||||||||
| Nine Months Ended | ||||||||
| June 30, 2021 | June 30, 2020 | |||||||
| Cash flows from operating activities: | ||||||||
Net loss | $ | (9,657,109 | ) | $ | (4,349,732 | ) | ||
Adjustments for noncash items | 2,380,648 | 540,945 | ||||||
Change in working capital items | (6,033,149 | ) | 495,384 | |||||
Net cash used in operating activities | (13,309,610 | ) | (3,313,403 | ) | ||||
Net cash provided by (used in) investing activities | (7,610 | ) | 15,532 | |||||
Net cash provided by financing activities | 13,953,703 | 3,864,307 | ||||||
Effect of exchange rate changes on cash and cash equivalents | 202,396 | 43,676 | ||||||
Increase in cash and cash equivalents during the period | 838,879 | 610,112 | ||||||
Cash and cash equivalents, beginning of period | 7,213,695 | 5,030,583 | ||||||
Cash and cash equivalents, end of period | $ | 8,052,574 | $ | 5,640,695 | ||||
SOURCE: Edesa Biotech, Inc.
View source version on accesswire.com:
https://www.accesswire.com/658971/Edesa-Biotech-Reports-Fiscal-3rd-Quarter-2021-Financial-Results
FAQ
What are the latest financial results for Edesa Biotech (EDSA)?
What clinical milestones has Edesa Biotech achieved?
How have Edesa's operational costs changed in 2021?
What is Edesa Biotech's current cash position?
